Real-World Impact of SABR on Stage I Non-Small Cell Lung 2 Cancer Outcomes at a Scottish Cancer Centre

Edinburgh Cancer Informatics Programme, Mark Stares*, Georgina Lewis, Maheva Vallet, Angus Killean, Giovanni Tramonti, Ailsa Patrizio, Melanie J Mackean, Stephen Harrow, Colin Barrie, Kirsty Maclennan, Sorcha Campbell, Tamasin Evans, Aisha Tufail, Peter S Hall, Iain Phillips

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Abstract: Introduction: Stereotactic ablative body radiotherapy (SABR) offers patients with stage I 28 non small-cell lung cancer (NSCLC) a safe, effective radical therapy option. The impact of introduc-29 ing SABR at a Scottish regional cancer centre was studied. Methods: The Edinburgh Cancer Centre 30 Lung Cancer Database was assessed. Treatment patterns and outcomes were compared across treat-31 ment groups (no radical therapy (NRT), conventional radical radiotherapy (CRRT), SABR and sur-32 gery) and across 3 time periods reflecting the availability of SABR (A, January 2012/2013 (pre-33 SABR); B, 2014/ 2016 (introduction of SABR); C, 2017/2019, (SABR established). Results: 1143 pa-34 tients with stage I NSCLC were identified. Treatment was NRT in 361 (32%), CRRT in 182 (16%), 35 SABR in 132 (12%) and surgery in 468 (41%) of patients. Age, performance status and comorbidities 36 correlated with treatment choice. Median survival increased from 32.5 months in time period A to 37 38.8 months in period B to 48.8 months in time period C. The greatest improvement in survival was 38 seen in patients treated with surgery between time periods A and C (HR 0.69 (95%CI 0.56-0.86), 39 p
Original languageEnglish
Publication statusPublished - 23 Feb 2023


  • Non small cell lung cancer
  • stage 1
  • stereotactic ablative radiotherapy
  • real-world clinical data


Dive into the research topics of 'Real-World Impact of SABR on Stage I Non-Small Cell Lung 2 Cancer Outcomes at a Scottish Cancer Centre'. Together they form a unique fingerprint.

Cite this